- Home
- XERS vs IMTX Comparison
XERS vs IMTX Comparison
Compare XERS & IMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- IMTX
- Stock Information
- Founded
- XERS 2005
- IMTX N/A
- Country
- XERS United States
- IMTX Germany
- Employees
- XERS N/A
- IMTX N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- IMTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- XERS Health Care
- IMTX Health Care
- Exchange
- XERS Nasdaq
- IMTX Nasdaq
- Market Cap
- XERS 628.7M
- IMTX 579.8M
- IPO Year
- XERS 2018
- IMTX N/A
- Fundamental
- Price
- XERS $5.16
- IMTX $4.34
- Analyst Decision
- XERS Strong Buy
- IMTX Strong Buy
- Analyst Count
- XERS 5
- IMTX 4
- Target Price
- XERS $6.10
- IMTX $16.67
- AVG Volume (30 Days)
- XERS 2.3M
- IMTX 420.3K
- Earning Date
- XERS 05-08-2025
- IMTX 05-20-2025
- Dividend Yield
- XERS N/A
- IMTX N/A
- EPS Growth
- XERS N/A
- IMTX N/A
- EPS
- XERS N/A
- IMTX 0.14
- Revenue
- XERS $222,551,000.00
- IMTX $161,336,577.00
- Revenue This Year
- XERS $31.75
- IMTX N/A
- Revenue Next Year
- XERS $21.09
- IMTX $4.92
- P/E Ratio
- XERS N/A
- IMTX $29.94
- Revenue Growth
- XERS 29.88
- IMTX 188.60
- 52 Week Low
- XERS $1.72
- IMTX $3.30
- 52 Week High
- XERS $6.07
- IMTX $13.77
- Technical
- Relative Strength Index (RSI)
- XERS 63.30
- IMTX 44.99
- Support Level
- XERS $4.26
- IMTX $3.94
- Resistance Level
- XERS $4.77
- IMTX $5.41
- Average True Range (ATR)
- XERS 0.28
- IMTX 0.34
- MACD
- XERS 0.08
- IMTX -0.01
- Stochastic Oscillator
- XERS 91.32
- IMTX 27.21
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
About IMTX Immatics N.V.
Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.